

**Amendments to the Claims:**

Please amend claims 1, 2, 19 and 26, cancel claims 55 and 56 and add new claims 81--103.

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, wherein said composition comprises:

a therapeutically effective amount of an extracellular matrix-binding fragment of Ang-1 protein ~~selected from the group~~ consisting of SEQ ID NO:1, ~~SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4~~, and/or a vector comprising a nucleic acid molecule that comprises the nucleotide sequence that encodes an extracellular matrix-binding fragment of Ang-1 protein ~~selected from the group~~ consisting of SEQ ID NO:1, ~~SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4~~.

2. (Currently amended) The pharmaceutical composition of claim 1 comprising a therapeutically effective amount of an extracellular matrix-binding fragment of Ang-1 protein ~~selected from the group~~ consisting of SEQ ID NO:1, ~~SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4~~.

3-18. (Canceled)

19. (Currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding; wherein said mutant Ang-1 is selected from the group consisting of:

a peptide having at least 60% homologous to Ang-1;

an Ang-1 mutant missing a linker domain;  
an Ang-1 mutant missing an N-terminal coiled-coil region; and  
an Ang-1 mutant having a serine at residue 265 in place of cysteine.

20-25. (Canceled)

26. (Currently amended) A pharmaceutical composition comprising  
a pharmaceutically acceptable carrier and  
a therapeutically effective amount of a mutant Ang-1 having angiogenesis promoting  
activity but which is not cleaved into a antagonist fragment; wherein said mutant Ang-1 is a  
peptide having at least 60% homologous to Ang-1.

27-52. (Canceled)

53. (Previously presented) A pharmaceutical composition comprising  
a) a pharmaceutically acceptable carrier and  
b) a therapeutically effective amount of an Ang-1 fragment with antagonist activity.

54. (Previously presented) The pharmaceutical composition of claim 53 further comprising  
Ang-2 protein.

55-80. (Canceled)

81. (New) The pharmaceutical composition of claim 54 wherein the Ang-1 fragment is an is  
selected from the group consisting of a SEQ ID NO:11 and SEQ ID NO:12.

82. (New) The pharmaceutical composition of claim 53 wherein the Ang-1 fragment is an is  
selected from the group consisting of a SEQ ID NO:11 and SEQ ID NO:12.

83. (New) The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is a peptide having at least 70% homologous to Ang-1.

84. (New) The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is a peptide having at least 80% homologous to Ang-1.

85. (New) The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is a peptide having at least 90% homologous to Ang-1.

86. (New) The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is a peptide having at least 95% homologous to Ang-1.

87. (New) The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is a peptide having at least 96% homologous to Ang-1.

88. (New) The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is a peptide having at least 97% homologous to Ang-1.

89. (New) The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is a peptide having at least 98% homologous to Ang-1.

90. (New) The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is a peptide having at least 99% homologous to Ang-1.

91. (New) The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is an Ang-1 mutant missing a linker domain.

92. (New) The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is an Ang-1 mutant missing an N-terminal coiled-coil region.

93. (New) The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is an Ang-1 mutant having a serine at residue 265 in place of cysteine.

94. (New) The pharmaceutical composition of claim 19 wherein the mutant Ang-1 having angiogenesis promoting activity but which have reduced or inactive extracellular matrix-binding is an Ang-1 mutant having an amino acid sequence selected from the group consisting of a SEQ ID NO:5. , SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10.

95. (New) The pharmaceutical composition of claim 26 wherein the mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment is a peptide having at least 70% homologous to Ang-1.

96. (New) The pharmaceutical composition of claim 26 wherein the mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment is a peptide having at least 80% homologous to Ang-1.

97. (New) The pharmaceutical composition of claim 26 wherein the mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment is a peptide having at least 90% homologous to Ang-1.

98. (New) The pharmaceutical composition of claim 26 wherein the mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment is a peptide having at least 95% homologous to Ang-1.

99. (New) The pharmaceutical composition of claim 26 wherein the mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment is a peptide having at least 96% homologous to Ang-1.

100. (New) The pharmaceutical composition of claim 26 wherein the mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment is a peptide having at least 97% homologous to Ang-1.

101. (New) The pharmaceutical composition of claim 26 wherein the mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment is a peptide having at least 98% homologous to Ang-1.

102. (New) The pharmaceutical composition of claim 26 wherein the mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment is a peptide having at least 99% homologous to Ang-1.

**UPN0003-100**  
**SERIAL NO.: 10/789,222**

**PATENT**  
**FILED 02/27/2004**

103. (New) The pharmaceutical composition of claim 26 wherein the mutant Ang-1 having angiogenesis promoting activity but which is not cleaved into a antagonist fragment is an Ang-1 mutant having an amino acid sequence selected from the group consisting of a SEQ ID NO:5. , SEQ ID NO:6, SEQ ID NO:9 and SEQ ID NO:10.